RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sartorius Stedim Biotech Stock

Sartorius Stedim Biotech P/S 2024

Sartorius Stedim Biotech P/S

5.99

Ticker

DIM.PA

ISIN

FR0013154002

WKN

A2AJKS

As of Dec 5, 2024, Sartorius Stedim Biotech's P/S ratio stood at 5.99, a -28.78% change from the 8.41 P/S ratio recorded in the previous year.

The Sartorius Stedim Biotech P/S history

Sartorius Stedim Biotech Aktienanalyse

What does Sartorius Stedim Biotech do?

Sartorius Stedim Biotech SA is a company specializing in the development, manufacturing, and marketing of products and services for the biopharmaceutical industry. It was formed in 2007 through the merger of two companies, Sartorius and Stedim Biotech, and is headquartered in Aubagne, France. The company has a history dating back to 1870 when Florenz Sartorius, a mechanic, founded a precision scale factory in Göttingen, Germany. Over the years, Sartorius became a leading provider of laboratory scales and equipment worldwide. In 1951, the company was renamed Sartorius AG and expanded into filtration technology. Stedim Biotech, on the other hand, was founded in 1957 as a manufacturer of plastic products and is based in Aubagne, France. It has since become a leading provider of products and services for the biopharmaceutical industry. Today, Sartorius Stedim Biotech SA operates in four business segments: bioprocess systems, laboratory equipment, services, and specialized products. Its bioprocess systems segment includes products and solutions for biopharmaceutical production such as fermenters, bioreactors, cryogenic storage tanks, and filtration systems. The laboratory equipment segment offers a wide range of lab products including scales, pipettes, and analysis devices. The services segment includes consulting, training, and technical services for the biopharmaceutical industry. Lastly, the specialized products segment provides a broad range of products for specific applications, such as disposable syringes for medication administration. Sartorius Stedim Biotech SA has developed a wide range of products for the biopharmaceutical industry, including fermenters and bioreactors for the production of biological drugs, filtration systems for protein purification and cell culture media, disposable syringes for medication administration, and laboratory equipment for sample analysis. The company's business model is to offer a comprehensive range of products and services for the biopharmaceutical industry. It focuses on high-quality and innovative products and services, as well as providing consultation and support to its customers in solving challenges in biopharmaceutical production. Overall, Sartorius Stedim Biotech SA is a leading provider of products and services for the biopharmaceutical industry. Its broad product range and consultancy and support services make it an important partner for the biopharmaceutical industry in the production of biological drugs. Sartorius Stedim Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Sartorius Stedim Biotech's P/S Ratio

Sartorius Stedim Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Sartorius Stedim Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Sartorius Stedim Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Sartorius Stedim Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Sartorius Stedim Biotech stock

What is the price-to-earnings ratio of Sartorius Stedim Biotech?

The price-earnings ratio of Sartorius Stedim Biotech is currently 5.99.

How has the price-earnings ratio of Sartorius Stedim Biotech changed compared to last year?

The price-to-earnings ratio of Sartorius Stedim Biotech has increased by -28.78% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Sartorius Stedim Biotech high compared to other companies?

Yes, the price-to-earnings ratio of Sartorius Stedim Biotech is high compared to other companies.

How does an increase in the price-earnings ratio of Sartorius Stedim Biotech affect the company?

An increase in the price-earnings ratio of Sartorius Stedim Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Sartorius Stedim Biotech affect the company?

A decrease in the price-earnings ratio of Sartorius Stedim Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Sartorius Stedim Biotech?

Some factors that influence the price-earnings ratio of Sartorius Stedim Biotech are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Sartorius Stedim Biotech pay?

Over the past 12 months, Sartorius Stedim Biotech paid a dividend of 2.88 EUR . This corresponds to a dividend yield of about 1.62 %. For the coming 12 months, Sartorius Stedim Biotech is expected to pay a dividend of 3.69 EUR.

What is the dividend yield of Sartorius Stedim Biotech?

The current dividend yield of Sartorius Stedim Biotech is 1.62 %.

When does Sartorius Stedim Biotech pay dividends?

Sartorius Stedim Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, May.

How secure is the dividend of Sartorius Stedim Biotech?

Sartorius Stedim Biotech paid dividends every year for the past 27 years.

What is the dividend of Sartorius Stedim Biotech?

For the upcoming 12 months, dividends amounting to 3.69 EUR are expected. This corresponds to a dividend yield of 2.07 %.

In which sector is Sartorius Stedim Biotech located?

Sartorius Stedim Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sartorius Stedim Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sartorius Stedim Biotech from 4/4/2024 amounting to 0.69 EUR, you needed to have the stock in your portfolio before the ex-date on 4/2/2024.

When did Sartorius Stedim Biotech pay the last dividend?

The last dividend was paid out on 4/4/2024.

What was the dividend of Sartorius Stedim Biotech in the year 2023?

In the year 2023, Sartorius Stedim Biotech distributed 2.52 EUR as dividends.

In which currency does Sartorius Stedim Biotech pay out the dividend?

The dividends of Sartorius Stedim Biotech are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Sartorius Stedim Biotech stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Sartorius Stedim Biotech

Our stock analysis for Sartorius Stedim Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius Stedim Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.